Skip to main content

Month: July 2025

AEHL Signs $50 Million Strategic Financing Agreement to Launch Bitcoin Acquisition Plan

New York, USA, July 29, 2025 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ:AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”) today announced that it has entered into a Securities Purchase Agreement (the “Agreement”) with a leading U.S.-based investment firm, Streeterville Capital, LLC, for a total financing amount of up to $50 million. The proceeds from this financing will be used exclusively to purchase Bitcoin (BTC), marking a major step forward in AEHL’s entry into the cryptocurrency asset space. Under the terms of the Agreement, Streeterville Capital will provide capital to the Company in tranches over a period of up to 24 months, in an amount not to exceed $50 million. AEHL will use these funds to gradually acquire Bitcoin based on market conditions. The Agreement clearly specifies that the financing...

Continue reading

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Watch the “What This Means” video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor “What This Means” segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company’s ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on...

Continue reading

Publication of the 2025 Interim Financial Report

Press Release Publication of the 2025 Interim Financial Report Paris, July 29, 2025 – 74Software announced today that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) its Interim Financial Report as of June 30, 2025. The 2025 Interim Financial Report is available to the public under the conditions set forth by applicable regulations and can be consulted on the 74Software Investor Relations website: click here A French version is also available on the website: click here About 74Software 74Software is an enterprise software group founded through the combination of Axway and SBS – independently operated leaders with unique experience and capabilities to deliver mission-critical software for a data driven world. A pioneer in enterprise integration solutions for 25 years, Axway supports major brands...

Continue reading

Avis Budget Group Announces Multi-Year Strategic Partnership with Waymo

PARSIPPANY, N.J., July 29, 2025 (GLOBE NEWSWIRE) — Avis Budget Group, Inc. (NASDAQ: CAR), a leading global provider of mobility solutions, today announced a multi-year strategic partnership with Waymo, the leader in self-driving technology, to launch and scale a fully autonomous ride-hailing service in Dallas. Through this agreement, Avis Budget Group will serve as Waymo’s fleet operations partner in Dallas, delivering end-to-end services including infrastructure, vehicle readiness, maintenance, and depot operations. Waymo will offer its ride-hailing service directly to the public via the Waymo app, while maintaining responsibility for validation and performance of the Waymo Driver. Initial testing is already underway in Dallas with the public launch slated for 2026. For over 75 years, Avis has been a leader in the rental car industry....

Continue reading

Expion360 to Host Second Quarter 2025 Financial Results Conference Call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern Time

REDMOND, Ore., July 29, 2025 (GLOBE NEWSWIRE) — Expion360 Inc. (Nasdaq: XPON) (the “Company”), an industry leader in lithium-ion battery power storage, will hold a conference call on Wednesday, August 13, 2025, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ended June 30, 2025. A press release detailing these results will be issued prior to the call. Expion360 Chief Executive Officer Brian Schaffner will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here. To access the call, please use the following information:Date: Wednesday, August 13, 2025Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Dial-in: 1-844-825-9789International...

Continue reading

AirJoule Technologies Announces Participation in Upcoming Investor Conferences

RONAN, Mont., July 29, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), the developer of the transformational AirJoule® system for separating pure water from air, today announced that it will be participating in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference Date: August 12, 2025Location: Boston, MA H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8-9, 2025Location: New York, NY At each conference, management will give a presentation and conduct one-on-one meetings with investors. If you would like to schedule a meeting with management at the above events, please contact Tom Divine at investors@airjouletech.com. Investors and interested parties can access the presentation from the conference by visiting...

Continue reading

Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery

Strategic Acquisition Positions Branded Legacy to Enter the Growing Naloxone and Vaccine Markets, Enhancing Shareholder Value; Leadership Transition Planned with Amin Janmohamed as New CEO and Chairman MELBOURNE, Fla., July 29, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company focused on innovative health and wellness solutions, today announced the execution of a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group, a pioneering health innovation company specializing in advanced intranasal drug delivery technologies. The LOI, fully executed by both parties, outlines the proposed acquisition of 100% of Bio-Legacy Evaluative Group’s equity interests, assets, intellectual property, and operations in exchange for $1.5 million worth of Branded Legacy’s...

Continue reading

Cannabix Technologies Receives Notice of Allowance from CIPO for Contactless Breath Analysis Patent Application

VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for patent application No. 3243445 entitled, “Contact-Free Breath Analysis Device and Method” to the Company. Recently the U.S. Patent and Trademark Office issued a notice of allowance for the same patent application filed in the United States. A notice of allowance indicates that the patent application has been approved by an examiner and that the Company can move forward with obtaining the patent granted upon payment of certain fees fee within a specified timeframe. This patent application is centered on innovations made by Cannabix and its dual mode contactless...

Continue reading

Bollinger Innovations Strengthens Balance Sheet by Eliminating all Warrants and $25.3 Million of Convertible Notes

Company increases shareholder equity by approximately $133 million Company expects shareholder equity to exceed Nasdaq listing requirements BREA, Calif., July 29, 2025 (GLOBE NEWSWIRE) — via IBN – Bollinger Innovations, Inc. (NASDAQ: BINI) (“Bollinger Innovations” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that the Company has eliminated all warrants and $25.3 million of convertible notes, strengthening its balance sheet. The Company entered into agreements with existing noteholders to exchange convertible notes and warrants into newly created preferred stock. “We have improved the Company’s financial position with the elimination of all warrants and $25.3 million of convertible notes,” said David Michery, CEO and chairman of Bollinger Innovations, Inc. “Our key investors continue to support...

Continue reading

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.